TOKYO--(BUSINESS WIRE)--R-Tech Ueno, Ltd. (RTU) (JASDAQ:4573) today announced that RTU and Sucampo Manufacturing and Research AG (SMR), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) (Sucampo), executed a License Agreement to develop, manufacture, and commercialize Unoprostone (Rescula®) in regions excluding Japan, Taiwan, Republic of Korea, the People’s Republic of China and North America (the SMR territory).
